Lobular Breast Cancer: Pathology, Biology, and Options for Clinical Intervention
- 20 August 2013
- journal article
- review article
- Published by Walter de Gruyter GmbH in Archivum Immunologiae et Therapiae Experimentalis
- Vol. 62 (1) , 7-21
Abstract
Lobular carcinoma is a breast cancer subtype comprising approximately 15 % of all breast cancer cases. Clinical diagnosis of this subtype is difficult due to a characteristic growth pattern that inhibits detection using palpation or standard X-ray mammography. While clinical intervention based on hormone antagonists has proven an effective strategy, hormone receptor negative or nonresponsive disease cannot be treated successfully, indicating the need for alternative curative approaches. In contrast to its well-defined histopathological characteristics that were first recognized a century ago, the surface of the underlying biology has only recently been scratched. Progress was made in understanding the biology of the disease, which will hopefully have its impact on future treatment modalities and initiate development of novel intervention strategies. Here, we review the pathological and molecular features of lobular breast cancer and report on the currently known mechanisms that control disease development and progression. Finally we will reflect on past, present, and future treatment options.Keywords
This publication has 164 references indexed in Scilit:
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- The Life History of 21 Breast CancersCell, 2012
- Invasive lobular breast cancer: subtypes and outcomeBreast Cancer Research and Treatment, 2012
- p53 mutations in classic and pleomorphic invasive lobular carcinoma of the breastCellular Oncology, 2012
- Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypesBreast Cancer Research and Treatment, 2011
- Use of cancer‐specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumorsGenes, Chromosomes and Cancer, 2010
- Founder and Recurrent CDH1 Mutations in Families With Hereditary Diffuse Gastric CancerJAMA, 2007
- Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease OutcomesThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 TrialJAMA, 2006
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindredHuman Mutation, 2002